This story is currently available in английский only — a translation isn't ready yet.
Critical Medicines Act aims to reduce Europe's reliance on Asian suppliers for pharmaceuticals.
ℹ️ Озвучка браузером · студийный голос ИИ скоро
The European Union has reached agreement on the Critical Medicines Act, a plan designed to reduce Europe's dependence on China and India for essential medicines and pharmaceutical ingredients, according to EurActiv.
The measure addresses supply chain vulnerabilities exposed during recent global health disruptions. By strengthening domestic and allied pharmaceutical production capacity, the EU aims to ensure reliable access to critical medicines during future crises. The agreement represents a strategic shift toward supply chain resilience and reduced geopolitical exposure in healthcare.
The EU has finalized the Critical Medicines Act to reduce its reliance on China and India for essential drugs and pharmaceutical ingredients by boosting domestic and allied production capacity. The agreement aims to shield Europe from future supply chain disruptions and geopolitical vulnerabilities in healthcare.
If you take regular medications, this affects your long-term access to affordable drugs—the EU's shift toward domestic production could increase prices in the short term but reduce shortages during crises. Pharmaceutical and chemical companies across Europe will see new investment and regulatory incentives, reshaping where medicines are manufactured and sourced.